

## ASCO 2024 ANNUAL MEETING ACCEPTED ABSTRACTS

### SWOG-Led Abstracts

- MULTIPLE Hershman D, Till C, Vaidya R, LeBlanc M, Unger J. Risk Prediction Model for Acute Care Use Among Advanced Cancer Patients on Clinical Trials. ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), poster, 2024. <https://meetings.asco.org/abstracts-presentations/233233>
- MULTIPLE\* Puztai L, Hoag J, Albain K, Barlow W, Stemmer S, Meisner A, Hortobagyi G, Shak S, Hayes D, Rae J, Baehner R, Sharma P, Kalinsky K. Development and validation of RSCLin N+ tool for hormone receptor-positive (HR+), HER2-negative (HER2-) node-positive breast cancer. ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), oral, 2024. [\*S1007,S8814] <https://meetings.asco.org/abstracts-presentations/232431>
- MULTIPLE Unger J, Andrews H, Levit L, McKelvey B, Stewart M, Dressler E, Flaherty K, Fredette P, (L) Jones H, Miller T, Onitilo A, Patel T, Bruinooge S, Garrett-Mayer L, Schenkel C. Impact of the COVID-19 Pandemic on Data Quality in Cancer Treatment Trials: A Meta-Analysis of Sponsor-Level Aggregate Data . ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), poster, 2024. <https://meetings.asco.org/abstracts-presentations/233243>
- MULTIPLE Unger J, Vaidya R, Fisch M, Jones S, Henry NL, Hershman D. Patient-reported fatigue and risk of treatment-related adverse events (AEs) in patients receiving systemic therapy in cancer clinical trials. ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), Rapid Oral Abstract, 2024. <https://meetings.asco.org/abstracts-presentations/231640>
- S0424 Mack P, Isa S, Hsieh M, Koh Y, Moon J, Tamiya A, Redman M, Albain K, Kelly K, Ambrosone C, Gray JE, Kubo A, Gandara D, Lara P, Kawaguchi T. Prospective “common arm” comparison of US SWOG S0424 and Japanese JME studies in early-stage non-small cell lung cancer (NSCLC): survival differences in the context of race, gender and smoking. ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), poster, 2024. <https://meetings.asco.org/abstracts-presentations/236959>
- S1007 Abdou Y, Hoag J, Barlow W, Gralow J, Meric-Berstam F, Albain K, Hayes D, Lin N, Perez E, Goldstein L, Chia S, Dhesy-Thind S, Rastogi P, Schott A, Racz J, Tripathy D, Hortobagyi G, Puztai L, Sharma P, Kalinsky K. Recurrence

score gene axes scores and outcomes by race and ethnicity in the RxPONDER trial. ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), Rapid Oral Abstract, 2024. <https://meetings.asco.org/abstracts-presentations/233535>

- S1007 Kalinsky K, Barlow W, Pathak H, Gralow J, Albain K, Hayes D, Lin N, Perez E, Goldstein L, Chia S, Rastogi P, Schott A, Shak S, Tripathy D, Hortobagyi G, Meric-Bernstam F, Sharma P, Puzstai L, Thompson A, Godwin A. Correlation of serum anti-Müllerian hormone (AMH) levels on identification of premenopausal patients (pts) with hormone receptor positive (HR+), HER2-negative, node-positive breast cancer most likely to benefit from adjuvant chemotherapy in SWOG S1007 (RxPONDER). ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), oral abstract session, 2024. <https://meetings.asco.org/abstracts-presentations/231752>
- S2107 Morris VK, Guthrie KA, Kopetz ES, Breakstone R, Karasic T, Hu I, Colby S, Fakih M, Gholami S, Gold PJ, Chiorean EG, Philip PA. SWOG S2107 - Randomized Phase II Trial of Encorafenib and Cetuximab with or Without Nivolumab for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer. ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), TIPS, poster, 2024. <https://meetings.asco.org/abstracts-presentations/238388>
- S1203 Raychaudhuri S, Othus M, Percival M, Garcia-Manero G, Appelbaum F, Erba H, Appelbaum J. Low rates of treatment discontinuation due to toxicity for patients with acute myeloid leukemia (AML) treated on SWOG S1203. ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), poster, 2024. <https://meetings.asco.org/abstracts-presentations/232599>
- S1216 Swami U, Jo Y, Narang A, Plets M, Chehade C, Gebrael G, Gupta S, Myint Z, Tangen C, Lara P, Thompson I, Hussain M, Dorff T, Lerner S, Agarwal N. Correlation of Body Mass Index (BMI) with survival outcomes in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): Analysis of Patient (pt) Level Data from SWOG 1216 study. ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), poster, 2024. <https://meetings.asco.org/abstracts-presentations/234451>
- S1404 LaPelusa M, Marcano D, Othus M, Grossmann A, Aushev V, Sridhar B, Renner D, Sethi H, Liu M, Tarhini A, Kirkwood J, Grossmann K, Moon J, Li H, Mashrun S, Khushalani N, Sharon E, Korde L, Ribas A, Patel S. Association between Postoperative Circulating Tumor DNA (ctDNA) and Recurrence-Free Survival (RFS) in Patients with Resected Stage III Melanoma - an Exploratory Analysis of SWOG S1404. ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), poster, 2024. <https://meetings.asco.org/abstracts-presentations/232941>

- S1600 Hamilton-Reeves J, Unger J, Holzbeierlein J, Lew DL, Mark J, Daneshmand S, Kukreja J, Lee E, Tabayoyong W, Hershman D, Fisch M, Henry NL. Effects of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes: Primary Results from the Randomized Phase III Double-Blind Clinical Trial (S1600). ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), oral presentation, oral abstract session, 2024. <https://meetings.asco.org/abstracts-presentations/231760>
- S1609 Chae Y, Dietrich E, Othus M, Il-Young Chung L, Kim H, Ryan C, Blanke CD, Patel S, Kurzrock R. Evaluation of mixed response in tumor size and survival in patients with rare cancers treated with dual checkpoint inhibitor therapy (DART SWOG S1609). ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), Rapid Oral Abstract Session, 2024. <https://meetings.asco.org/abstracts-presentations/234025>
- S1609 Othus M, Patel S, Chae YK, Dietrich E, Streicher H, Sharon E, Kurzrock R. Correlations Between First Cycle Toxicity and Overall Survival in Patients with Rare Cancers Treated with Immune Checkpoint Inhibitors (NCI/SWOG S1609). ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), poster, 2024. <https://meetings.asco.org/abstracts-presentations/233922>
- S1701 Tsao A, Hsieh M, Koczywas M, Tu J, Riess J, Tanvetyanon T, Ma B, Zhao Y, Redman M, Edelman M, Gandara D, Kelly K, Gray J. A Randomized Phase II trial of Carboplatin-Paclitaxel with or without Ramucirumab in Patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma (SWOG S1701). ASCO Annual Meeting (May 31-June 4, 2024, Chicago, IL), poster, 2024. <https://meetings.asco.org/abstracts-presentations/237851>
- S1714 Trivedi M, Unger J, Hershman D, Darke A, Hertz D, Brannagan T, Smith S, Schneider B, Irvin W, Hathaway A, Vander Woude A, Gudena V, Cabrera-Galean P, Orsted M, LeBlanc M, Henry NL, Fisch MJ. Risk Prediction Model for Taxane-Induced Peripheral Neuropathy in Patients with Early-Stage Cancer Receiving Taxane Therapy: SWOG S1714 (NCT# 03939481). ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), oral, 2024. <https://meetings.asco.org/abstracts-presentations/232442>
- S1800D Wrangle J, Redman M, Husain H, Reckamp K, Stinchcombe T, Edelman M, Leal T, Faller B, Minichiello K, Borghaei H, Herbst RS, Gray JE. Lung-MAP S1800D: A Phase II/III Study of N-803 (ALT-803) plus Pembrolizumab versus Standard of Care in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Previously Treated with Anti-PD-1

or Anti-PD-L1 Therapy. ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), poster, 2024.

<https://meetings.asco.org/abstracts-presentations/233966>

- S1937 Sadeghi S, Plets M, Lara P, Tangen C, Berg S, Brown J, Bangs R, Nakagawa D, Daneshmand S, Thompson I, Flaig T, Petrylak D, Lerner S. A phase III randomized trial of eribulin (E) with gemcitabine vs standard of care (SOC) for metastatic urothelial carcinoma (UC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937- Updated Design. ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), TIPS, poster, 2024. <https://meetings.asco.org/abstracts-presentations/238437>
- S2012 Zhen D, Moseley A, Chiorean EG, Burgess E, Swisher E, Gay C, Byers L, Wistuba I, Mahdi H, Starr J, Othus M, Chae Y, Kurzrock R. SWOG S2012: Randomized Phase II/III Trial of First Line Platinum (P) / Etoposide (E) with or without Atezolizumab (NSC #783608) in Patients with Advanced or Metastatic Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas (NEC). ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), TIPS, poster, 2024. <https://meetings.asco.org/abstracts-presentations/238397>
- S2107 Morris VK, Guthrie KA, Kopetz ES, Breakstone R, Karasic T, Hu I, Colby S, Fakhri M, Gholami S, Gold PJ, Chiorean EG, Philip PA. SWOG S2107 - Randomized Phase II Trial of Encorafenib and Cetuximab with or Without Nivolumab for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer. ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), TIPS, poster, 2024. <https://meetings.asco.org/abstracts-presentations/238388>
- S2213 Hagen P, Hoering A, Sidana S, Parker T, Walker B, Sanchurawala V, Zonder J, Kourelis T, DSouza A, Landau H, Rosenthal A, Ailawadhi S, Orlowski R. S2213, ?A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (DARA-VCD) Induction Followed by Autologous Stem Cell Transplant or DARA-VCD Consolidation and Daratumumab Maintenance in patients with Newly Diagnosed AL Amyloidosis. ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), poster, 2024. <https://meetings.asco.org/abstracts-presentations/238199>
- S2302 Carrizosa D, Miao J, Reckamp K, Dragnev K, Hesketh P, Iams W, Henick B, Czerlanis C, DeSanto F, Sundstrom J, Johnson J, Gansauer L, Groller T, Redman M, Herbst R, Gray J. Multi-stakeholder, Intentional Outreach for Improving Representative Recruitment in Pragmatic ? Lung (SWOG S2302). ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), poster, 2024. <https://meetings.asco.org/abstracts-presentations/232521>

S2302 Reckamp K, Redman M, Dragnev K, Iams W, Henick B, Miao J, Carrizosa D, Herbst RS, Gray J. SWOG S2302, PRAGMATICA - LUNG: A Prospective Randomized Study of Ramucirumab plus Pembrolizumab (PR) versus Standard of Care (SOC) for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer. ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), TIP, poster, 2024. <https://meetings.asco.org/abstracts-presentations/238548>

## Co-Led Abstracts

C/S80405 Ashouri K, Yan Y, Millstein J, Soni S, Algaze S, Mittal P, Wong A, Lo J, Torres-Gonzalez L, Jayachandran P, Zhang W, Meyer A, Battaglin F, Lenz H-J. Clinical and molecular characterization of AXL in colorectal cancer: CALGB (Alliance)/SWOG 80405 and real-world data. ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), poster, 2024. <https://meetings.asco.org/abstracts-presentations/234130>

C/S80405 Battaglin F, Millstein J, Yang Y, Soni S, Algaze S, Ashouri K, Mittal P, Lo J, Torres-Gonzalez L, Jayachandran P, Zhang W, Ou F, Venook A, Innocenti F, Lenz H-J. Expression of metabolic genes associated with changes in brain structure across the lifespan affects patients (pts) outcomes in metastatic colorectal cancer (mCRC): Data from CALGB/SWOG 80405 (Alliance). ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), poster, 2024. <https://meetings.asco.org/abstracts-presentations/234131>

C/S80405 Battaglin F, Yang Y, Millstein J, Soni S, Algaze S, Ashouri K, Mittal P, Jayachandran P, Wong A, Lo J, Torres-Gonzalez L, Zhang W, Ou F, Venook A, Innocenti F, Mumenthaler S, Lenz H-J. Impact of GABA pathway genes expression on first-line treatment outcomes in patients (pts) with metastatic colorectal cancer (mCRC): Data from CALGB/SWOG 80405 (Alliance). ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), poster, 2024. <https://meetings.asco.org/abstracts-presentations/237107>

C/S80405 Hashimoto T, Nakamura Y, Yang Y, Battaglin F, Innocenti F, Venook A, Makiyama A, Boku S, Machida N, Takahashi N, Kadowaki S, Komatsu Y, Kudo T, Oki E, Kato T, Kagawa Y, Fugisawa T, Bando H, Lenz H-J, Yoshino T. Prognostic impact of HER family expressions for metastatic colorectal cancer (mCRC): SCRUM-Japan MONSTAR-SCREEN-2 and CALGB/SWOG 80405 trial (Alliance) international collaboration. ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), poster, 2024. <https://meetings.asco.org/abstracts-presentations/237056>

C/S80405 Millstein J, Battaglin F, Yang Y, Soni S, Algaze S, Jayachandran P, Ashouri K, Mittal P, Torres-Gonzalez L, Zhang W, Ou F, Venook A, Innocenti F, Mumenthaler S, Hashimoto T, Fugisawa T, Nakamura Y, Bando H, Yoshino T, Lenz H-J. Upstream regulation of neurotransmitter signaling genes in metastatic colorectal cancer (mCRC) patients: data from CALGB/SWOG 80405 trial (Alliance) and MONSTAR-SCREEN-2. ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), poster, 2024. <https://meetings.asco.org/abstracts-presentations/237087>

C/S80405 Algaze S, Yang Y, Millstein J, Battaglin F, Soni S, Mittal P, Ashouri K, Jayachandran P, Arai H, Ho Lo J, Zhang W, Torres-Gonzalez L, Wong A, Lenz H-J. Time to target TIM-3 in colorectal cancer: TIM-3 expression to predict survival outcomes in patients in CALGB (Alliance)/SWOG 80405. ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL), poster, 2024. <https://meetings.asco.org/abstracts-presentations/237100>

NRG-GI004/SWOG-S1610 Rocha Lima CM, Yothers G, Puhalla S, Sanoff H, Cohen D, Guthrie K, Henry N, Ganz P, Kopetz S, Lucas P, Blanke C, Jacobs S, Hong T, Wolmark N, Hochster H, George T, Overman M. NRG-GI004/SWOG-S1610: Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC). ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), TIP, poster, 2024. <https://meetings.asco.org/abstracts-presentations/238380>

### **Abstracts Led by Other Groups with SWOG Representation**

A011401 Ligibel J, Ballman K, McCall L, Goodwin P, Weiss A, Crane T, Irwin M, Thomson C, Hahn O, Spears P, Hershman D, Paskett E, Hopkins J, Bernstein V, Stearns V, White J, Wadden T, Winer E, Carey L, Partridge A. Effect of a weight loss intervention (WLI) on exercise behaviors in women with breast cancer: Results from the Breast Cancer Weight Loss (BWEL) Trial . ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), poster, 2024.

A011502 Gandhi S, Ballman K, Holmes M, Visvanathan K, Symington B, Carvan M, Matyka C, Weiss A, Winer E, Carey L, Partridge A, Chen W. Association of Higher baseline stress and pain associated with clinical outcomes: A secondary analysis

from Alliance A011502. ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), Rapid Oral Abstract Session, 2024.

- A011502 Gandhi S, Ballman K, Holmes M, Visvanathan K, Symington B, Carvan M, Matyka C, Weiss A, Winer E, Carey L, Partridge A, Chen W. Correlation of Stress, depression, sleep, and pain vary with race and BMI: Secondary analysis from A011502. ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), publication only, 2024.
- A051701 Abramson J, Geyer S, Pederson L, Giri S, Hsi E, Little R, Gore S, Landsburg D, Cherng H, Kahl B, Friedberg JW, Bartlett N, Leonard J. Randomized Phase II/III Study of R-CHOP +/- Venetoclax in Previously Untreated MYC/BCL2 Double Expressor Diffuse Large B Cell Lymphoma (DLBCL): Alliance A051701. ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), Rapid Oral Abstract Session, 2024.
- A091902 Grilley Olson J, Allred J, Schuetze S, Davis E, Poklepovic A, Wagner M, Riedel R, Hartranft A, Xu-Welliver M, Berg S, George S, Robinson S, Googe P, D'Angelo S, Schwartz G. Alliance A091902: A multicenter randomized phase II trial of paclitaxel (P) with or without nivolumab (N) in patients (pts) with advanced angiosarcoma (AS). ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), Rapid Oral Abstract Session, 2024.
- EA1211 Hennessy M, Gatsonis C, Jacene H, Connolly R, Burnette B, Stringer-Reasor E, Romanoff J, Taurone A, O'Sullivan C, Le-Petross H, Lawhn-Heath C, Stearns V, Fowler A, Tang S, Sepulveda K, DeMichelle A, Mankoff D, Wolff A. Interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy: ECOG-ACRIN EA1211/DIRECT Trial. ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), TIP Poster, 2024.
- EA8153 Kyriakopoulos C, Chen Y, Jeraj R, Duan F, Luo J, Antonarakis E, Tripathi A, Kosoff D, Garje R, Pachynski R, Parikh R, Harzstark A, Adra N, Maughan B, Zakharia Y, Corn P, Liu G, Carducci M. Cabazitaxel with abiraterone versus abiraterone alone randomized trial for extensive disease following docetaxel: The CHARTED2 trial of the ECOG-ACRIN Cancer Research Group (EA8153). ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), LBA, Oral Abstract Session, 2024.
- EAY191-A6 Shergill A, Liao C, Elsaid M, Al Baghdadi T, Ji Y, Feldman D, George S, O'Reilly E, Meyerhardt J, Berg S, Schwartz G, Munster P, Bekail-Saab T, Abou-Alfa G, Shroff R, Shapiro G. EAY191-A6: FOLFOX in Combination with Binimetinib as 2nd-Line Therapy for Patients with Advanced Biliary Tract Cancers (BTCs) with MAPK Pathway Alterations: A ComboMATCH Treatment Trial. ASCO Annual Meeting (May 31 - June 4, 2024, Chicago, IL ), poster, 2024.